Pre-earnings brief
Reports
Wed, May 6, 2026
Est. EPS
$1.18
Est. revenue
$874M
Implied move
±4.5%
EPS beat rate
13%
Royalty Pharma plc is a healthcare company that specializes in acquiring and managing pharmaceutical royalties. With a market cap of $25 billion, it plays a significant role in the pharmaceutical industry by providing funding for drug development and commercialization.
Last quarter
In the last quarter, Royalty Pharma reported disappointing earnings, missing analyst expectations. The company continues to focus on expanding its portfolio of royalties.
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
+5.28%
Avg 1-day reaction
+0.00%
Analysts expect Royalty Pharma to report earnings of $1.18 per share on revenues of $874 million. The market is cautiously optimistic about the company's ability to meet these targets.
Bull case
If Royalty Pharma exceeds earnings expectations, it could signal strong demand for its royalty agreements and potentially lead to a positive reassessment of its growth prospects.
Bear case
Conversely, if the company fails to meet expectations, it may raise concerns about its revenue growth and profitability, leading to a negative market reaction.
Key metrics to watch
EPS
$1.18Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$874MTotal revenue helps gauge the company's overall sales performance and market demand for its royalty agreements.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $1.18?
The market will closely watch this figure as it directly reflects the company's profitability and could influence investor sentiment.
Q2
What are the revenue figures compared to the consensus of $874 million?
Revenue performance is critical for assessing the company's growth trajectory and ability to generate cash flow.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for revenue growth from new royalty agreements that have not yet been fully recognized in forecasts.
Supporting evidence
The company's recent acquisitions may provide unexpected revenue boosts not reflected in current estimates.
Options pricing suggests a significant move, indicating that traders expect a surprise in either direction.
Key risk
If the company announces new partnerships or acquisitions that significantly enhance its royalty portfolio, it could challenge current revenue expectations.
Pre-commit to what would confirm each case.
The market is debating whether Royalty Pharma can sustain its growth and profitability in a competitive environment.
Bull confirmed if
An EPS of $1.20 or higher would confirm the bull case and indicate strong operational performance.
Bear confirmed if
An EPS below $1.15 would likely confirm the bear case and raise concerns about the company's profitability.
What the market is pricing for the move.
Implied Move
±4.5%
The options market is pricing in a potential move of about 4.5% in either direction following the earnings report.
30d HV
21.5%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$474,407.48
8,252 sh
1 insider
Net
$474,407.48
Net selling
Most Active Insiders· 2 open-market trades
$474,407.48
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
87.68%
of float
Insider
6.49%
of float
Holders
997
institutions
Top Holders· as of Jun 2026
Morgan Stanley
42,931,597 sh · $2.4B
9.64%
-1.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Royalty Pharma beats expectations, history suggests the stock could rise significantly, confirming strong demand for its royalties.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A miss could lead to a sharp decline in the stock, with historical patterns suggesting an average drop of around 3.7%.
The lines on the call that would change the story.
Recent Transactions
Sep 28, 2026 · @ $57.88
4,126 sh
$238,812.88
Oct 5, 2026 · @ $57.10
4,126 sh
$235,594.60
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Capital International Investors
35,273,770 sh · $2.0B
7.92%
0.8%
Blackrock Inc.
27,832,977 sh · $1.6B
6.25%
7.4%
FMR, LLC
24,513,814 sh · $1.4B
5.51%
-2.5%
State Street Corporation
12,338,229 sh · $700.3M
2.77%
12.3%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.